GLPG Articles, Galapagos NV - From 06/14/24

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announced that it will present encouraging new d...

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR ...

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV ((Euronext &amp, NASDAQ:GLPG) announced today that its Boar...

Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs...

Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announces that all resolutions proposed at the c...

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymph...

Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...

Publication of annual report for financial year 2023 Annual Shareholders' Meeting resolutions include approval of revised Remuneration Polic...

Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announced that during its meeting of 26 March 20...

Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current f...